Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2 in pediatric cancer: innocent until proven guilty.

The oncologist - 1 Aug 2005

Gilbertson Richard J

Abstract excerpt

Adult oncologists and their research colleagues have "led the charge" in the war on cancer. Their efforts have generated effective new chemotherapies that target cancer causing molecular alterations. It is hoped that these successes will be repeated within the pediatric oncology community. Testing whether molecular targeted therapies of adult cancers are also effective against childhood cancers might allow the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Child
Share to ERBB2 gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Neoplasms

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 16079318
DOI: 10.1634/theoncologist.10-7-508

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2 in pediatric cancer: innocent until proven guilty.PMID 16079318Read ↗

Fine-Tuning the Relevance of Molecular Targets to Pediatric Cancer: Addressing Additional Layers of Complexity.Semantic proximity Read ↗

ErbB-targeted therapeutic approaches in human cancerSemantic proximity Read ↗

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid CancersSemantic proximity Read ↗

ErbB receptors: from oncogenes to targeted cancer therapiesSemantic proximity Read ↗

Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.Semantic proximity Read ↗

Pediatric molecular oncology. Past as prologue to the future.Semantic proximity Read ↗

ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary CarcinomasSemantic proximity Read ↗

Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date.Semantic proximity Read ↗

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood CancersSemantic proximity Read ↗

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.Semantic proximity Read ↗

Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development.Semantic proximity Read ↗

Protection against mammary tumor growth by vaccination with full-length, modified humanErbB-2 DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.